Netherlands· NL-4ec1010a748c
Yuvanci 10 mg/20 mg filmomhulde tabletten
A macitentan and tadalafil product containing macitentan + tadalafil, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Macitentan and tadalafil is registered in 11 of 19 countries.
Countries holding a registration under ATC C02KX54 (macitentan and tadalafil), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Macitentan and tadalafil · ATC C02KX54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MACITENTAN + TADALAFIL
- Manufacturer
- Janssen-Cilag International NV
- Country
- Netherlands (NL)
- ATC code
- C02KX54
- ATC class
- Macitentan and tadalafil
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1859
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Macitentan and tadalafil in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandYuvanciJanssen-Cilag International NV
- CzechiaYUVANCIJanssen-Cilag International N.V., Beerse
- SpainYUVANCI 10 MG/20 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- United StatesOPSYNVIActelion Pharmaceuticals US, Inc.
- IcelandYuvanciJanssen-Cilag International NV*
- PolandYuvanciJanssen-Cilag International N.V.
- SwedenYuvanci 10 mg/20 mg Filmdragerad tablettJanssen-Cilag International NV
- IrelandYuvanci 10 mg/20 mg film-coated tabletsJanssen Pharmaceutica NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yuvanci
- Liechtenstein · Yuvanci
- Norway · Yuvanci
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b217f793-0ea4-4fb2-938c-4e75f6764bd9 GET /v1/drugs/b217f793-0ea4-4fb2-938c-4e75f6764bd9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/yuvanci-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Macitentan and Tadalafil",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131787",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"GLYCEROLTRIACETAAT (E 1518)",
"HYDROXYPROPYLCELLULOSE, LAAG GESUBSTITUEERD (E 463a)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE (E 464)",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"NATRIUMZETMEELGLYCOLAAT",
"POLYSORBAAT 80 (E 433)",
"POVIDON K 30 (E 1201)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"MACITENTAN",
"TADALAFIL"
],
"leaflet_url": null,
"authorised_at": "2024/09/27",
"procedure_number": "EMEA/H/C/005001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1859",
"additional_monitoring": "N"
}See everything about macitentan and tadalafil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.